Strategic report Governance & remuneration Financial statements Investor information Financial record Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2014.
12 months 2014 Q4 2014 Income statement total m CER% % m CER% % Turnover Pharmaceuticals and Vaccines 18,670 6 12 5,070 7 10 Consumer Healthcare 4,336 11 18 1,116 7 10 Total turnover 23,006 7 13 6,186 7 10 Cost of sales 7,323 11 15 2,029 18 20 Selling, general and administration 8,246 4 3 2,207 4 Research and development 3,450 8 12 979 7 9 Royalty income 310 18 20 67 31 32 Other operating income 700 347 Operating profit 3,597 40 49 691 69 72 Net finance costs 659 171 profit on disposal of interest in associates and joint ventures Share of after tax profits of associates and joint ventures 30 11 profit before taxation 2,968 46 55 531 77 79 Taxation 137 494 Tax rate % 4.6% 93.0 % profit after taxation for the period 2,831 41 50 1,025 56 59 profit attributable to non-controlling interests 75 8 profit attributable to shareholders 2,756 1,033 Basic earnings per share pence 57.3p 40 49 21.5p 55 58 Diluted earnings per share pence 56.7p 21.3p Income statement core Total turnover 23,006 3 10 6,186 5 8 Cost of sales 6,535 3 8 1,798 3 6 Selling, general and administration 7,074 2 9 1,864 2 5 Research and development 3,113 4 8 821 8 9 Royalty income 310 18 20 67 31 32 Operating profit 6,594 6 15 1,770 9 12 Net finance costs 646 168 Share of after tax profits of associates and joint ventures 30 11 profit before taxation 5,978 6 16 1,613 10 14 Taxation 1,172 246 Tax rate % 19.6% 15.3% profit after taxation for the period 4,806 2 12 1,367 2 6 profit attributable to non-controlling interests 222 52 profit attributable to shareholders 4,584 1,315 Adjusted earnings per share pence 95.4p 1 12 27.3p 1 6 The calculation of core results is described on page 52.
CER% represents growth at constant exchange rates.
% represents growth at actual exchange rates.
